Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency Anemia
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The safety, tolerability, pharmacokinetics and pharmacodynamics of Z-213 will be investigated
in patients with iron-deficiency anemia after administration of a single dose (100 mg, 500
mg, 800 mg or 1,000 mg iron).